Compare Merck & Co., Inc. (MRK) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Norfolk Southern Corporation — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Norfolk Southern Corporation trades at $333 (market cap $75.23B). The key difference: Merck & Co., Inc. is far larger — about 4.1× Norfolk Southern Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | NSC | |
|---|---|---|
Market Cap | $307.25B | $75.23B |
Sector | Health | Technology |
52-Week High | $129.52 | $340.16 |
52-Week Low | $77.60 | $272.35 |
Enterprise Value | $350.66B | $90.99B |
Dividend Yield | 2.73% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Norfolk Southern (NSC) trades at $334.97, down 1.53% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Key developments include the pending Q2 2026 earnings report on July 23, 2026, and ongoing regulatory review of the proposed merger with Union Pacific, which dominates recent news coverage.
The investment outlook is cautiously optimistic, supported by earnings momentum and a consensus price target of $344.40 offering modest upside. Risks include potential regulatory hurdles for the merger, declining revenue projections for 2026, and elevated valuation multiples. The stock's current price near resistance levels suggests near-term volatility around earnings could present entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
